3-Nitrobenzeneacetic Acid

1877-73-2

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise thatΩ is market-oriented and realizes industrial development €through R&D innovation and technology transformation.

key word:

innovative Pharmaceutical

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health i₩ndustry finance platform company integrating pharm>aceutical, intelligent medical, bio pharmaceutical R&D, industrial production and↑ sales.

The chemical reactions involved in the existing products include Foucaul&t reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, ☆fluorination reaction, chlorination reaction, bromination reaction, diazotization reaction,≤ format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In Oc tober 2006, Sitagliptin phosphate Januvia was approv±ed by FDA as the first DPP4 inhibitor for the treatment oεf type ⅱ diabetes mellitus. The characteristics of this drug are that it can stimula↓te insulin secretion while reducing hunger without causing wei$ght gain. Hypoglycemia and edema will not occur, and it is suitable for diabetic patienσts with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orient'ed and realizes industrial development through R&D innovation and technology transformation.←

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the m<ost important products for the treatment of arthritis. It is well tolerate←d and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor a₩ntagonists. In clinical application, it has good therapeutic effect on atλopic asthma and other types of bronchial asthma, and the market prospect is huge. In the ∞major category of asthma drugs, leukotriene receptor antagonists have the fastest growing ®market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpris$e that is market-oriented and realizes industrial development through R&D innovation and teαchnology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second ✘drug approved by FDA for Alzheimer's disease in the United States. Its t↓reatment reaches the target dose and has low toxic and side effects. It has been w↓idely recognized by our medical community, and good tolφerance is its biggest advantage. In October 1999, Donepezil was launched$ in China under the trade name "Aricept", which is the main chemical drug ♣against Alzheimer's disease. At present, CFDA has approved a number of dome stic enterprises to produce donepezil preparations, the main dosage forms areσ tablets, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squib≥b/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member states. Th‍e world's first drug approved to prevent venous thromboembolism (VTE) in adult patients undergoing  elective hip or knee replacement. From June 2019 to June 2020, tφhe annual sales of apixaban products overseas reached about $15.4 billioεn, with a year-on-year growth of nearly 32%, and th✘e API consumption reached about 23,960 kg, with a year-on-year growth ∞of about 28%. Compared with its main competitor, Rivaroxaban, the drug's annual o←verseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmac★eutical enterprise that is market-oriented and realizes industri↑al development through R&D innovation and technology transformatio÷n.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme£. On December 29, 2004, it was approved by FDA for the treatment of reβfractory or relapsed acute lymphoblastic leukemia (ALL) in children★.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tec✔h pharmaceutical enterprise that is market-oriented and realizes industrial development through •R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you n‍eed other services, E-mail: 2880705932@qq.com
Submit